【CLAIMS】

【Claim 1】

A pharmaceutical combination preparation comprising a fimasartan, a pharmaceutically acceptable salt thereof, an isomer thereof, or a hydrate or a solvate thereof; a rosuvastatin, a pharmaceutically acceptable salt thereof, an isomer thereof, or a hydrate or a solvate thereof; and a meglumine.

【Claim 2】

The pharmaceutical combination preparation according to claim 1, wherein the pharmaceutically acceptable salt of the fimasartan is a fimasartan potassium.

【Claim 3】

The pharmaceutical combination preparation according to claim 1, wherein the hydrate is a fimasartan potassium trihydrate.

【Claim 4】

The pharmaceutical combination preparation according to claim 1, wherein the fimasartan, the pharmaceutically acceptable salt thereof, the isomer thereof, or the hydrate or the solvate thereof are comprised 5.0 mg - 240.0 mg per unit dosage form.

【Claim 5】

The pharmaceutical combination preparation according to claim 1, wherein the rosuvastatin, the pharmaceutically acceptable salt thereof, the isomer thereof, or the hydrate or the solvate thereof are a rosuvastatin calcium.

【Claim 6】

The pharmaceutical combination preparation according to claim 1, wherein ingredients of the rosuvastatin are comprised 5.0 mg - 20.0 mg per unit dosage form.

【Claim 7】

The pharmaceutical combination preparation according to claim 1, wherein the meglumine is comprised 1.0 - 30.0 wt% based on the total weight of the combination preparation.

【Claim 8】

The pharmaceutical combination preparation according to claim 1, wherein the combination preparation is for treatment of cardiovascular diseases.

【Claim 9】

The pharmaceutical combination preparation according to claim 8, wherein the cardiovascular diseases are selected from hypertension, diabetes, obesity, hyperlipidemia, coronary arterial diseases, chronic stable angina, vasospastic angina,

stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, impaired glucose tolerance, preliminary diabetes, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive impairments, dementia and combinations thereof.

【Claim 10】

The pharmaceutical combination preparation according to any one of claims 1-9, wherein at least one of a stabilizer, a binder, a disintegrant or a lubricant is further comprised.

【Claim 11】

The pharmaceutical combination preparation according to claim 10, wherein the stabilizer is comprised 1.0 - 50.0 wt% based on the total weight of the combination preparation.

【Claim 12】

The pharmaceutical combination preparation according to claim 10, wherein the binder is comprised 0.2 - 5.0 wt% based on the total weight of the combination preparation.

【Claim 13】

The pharmaceutical combination preparation according to claim 10, wherein the disintegrant is comprised 2.0 - 30.0 wt% based on the total weight of the combination preparation.

【Claim 14】

The pharmaceutical combination preparation according to claim 10, wherein the lubricant is comprised 0.2 - 5.0 wt% based on the total weight of the combination preparation.

【Claim 15】

The pharmaceutical combination preparation according to claim 10, wherein the diluent is comprised 15.0 - 90.0 wt% based on the total weight of the combination preparation.

【Claim 16】

The pharmaceutical combination preparation according to any one of claims 1-9, wherein the combination preparation is in a form of a tablet.

【Claim 17】

The pharmaceutical combination preparation according to claim 16, wherein the combination preparation is a form of a coated tablet which additionally comprises a coating layer on the exterior.

【Claim 18】

A pharmaceutical composition comprising the combination preparation according to any one of the claims 1-17.

【Claim 19】

A method of treating cardiovascular diseases comprising administration of therapeutically effective dose of the

combination preparation according to any one of claims 1-17.

【Claim 20】

The method of treating cardiovascular diseases according to claim 19, wherein the cardiovascular diseases are selected from hypertension, diabetes, obesity, hyperlipidemia, coronary arterial diseases, chronic stable angina, vasospastic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, impaired glucose tolerance, preliminary diabetes, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive impairments, dementia and combinations thereof.

【Claim 21】

A use of the combination preparation for preparation of medicaments for treatment of cardiovascular diseases according to any one of claims 1-17.

【Claim 22】

A use of the combination preparation for treatment of cardiovascular diseases according to any one of claims 1-17.

CLAIMS

1. A pharmaceutical combination preparation comprising, a granular part comprising fimasartan, a pharmaceutically acceptable salt thereof, an isomer thereof, or a hydrate or a solvate thereof;

and a mixed part comprising a rosuvastatin, a pharmaceutically acceptable salt thereof, an isomer thereof, or a hydrate or a solvate thereof, and a meglumine.

2. The pharmaceutical combination preparation according to claim 1, wherein the pharmaceutically acceptable salt of the fimasartan is a fimasartan potassium.

3. The pharmaceutical combination preparation according to claim 1, wherein the hydrate is a fimasartan potassium trihydrate.

4. The pharmaceutical combination preparation according to claim 1, wherein the fimasartan, the pharmaceutically acceptable salt thereof, the isomer thereof, or the hydrate or the solvate thereof are comprised 5.0 mg - 240.0 mg per unit dosage form.

5. The pharmaceutical combination preparation according to claim 1, wherein the pharmaceutically acceptable salt of rosuvastatin is a rosuvastatin calcium.

6. The pharmaceutical combination preparation according to claim 1, wherein ingredients of the rosuvastatin are comprised 5.0 mg - 20.0 mg per unit dosage form.

7. The pharmaceutical combination preparation according to claim 1, wherein the meglumine is comprised 1.0 – 30.0 wt% based on the total weight of the

combination preparation.

8. The pharmaceutical combination preparation according to claim 1, wherein the combination preparation is for treatment of cardiovascular diseases..

9. The pharmaceutical combination preparation according to claim 8, wherein the cardiovascular diseases are selected from hypertension, diabetes, obesity, hyperlipidemia, coronary arterial diseases, chronic stable angina, vasospastic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, impaired glucose tolerance, preliminary diabetes, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive impairments, dementia and combinations thereof.

10. The pharmaceutical combination preparation according to any one of claims 1-9, wherein at least one of a stabilizer, a binder, a disintegrant, a lubricant or a diluent is further comprised.

11. The pharmaceutical combination preparation according to claim 10, wherein the stabilizer is comprised 1.0 – 50.0 wt% based on the total weight of the combination preparation.

12. The pharmaceutical combination preparation according to claim 10, wherein the binder is comprised 0.2 – 5.0 wt% based on the total weight of the combination preparation.

13. The pharmaceutical combination preparation according to claim 10, wherein the disintegrant is comprised 2.0 – 30.0 wt% based on the total weight of the combination preparation.

14. The pharmaceutical combination preparation according to claim 10, wherein the lubricant is comprised 0.2 – 5.0 wt% based on the total weight of the combination preparation.

15. The pharmaceutical combination preparation according to claim 10, wherein the diluent is comprised 15.0 – 90.0 wt% based on the total weight of the combination preparation.

16. The pharmaceutical combination preparation according to any one of claims 1-9, wherein the combination preparation is in a form of a tablet.

17. The pharmaceutical combination preparation according to claim 16, wherein the combination preparation is a form of a coated tablet which additionally comprises a coating layer on the exterior.